Glucosamine, a widely consumed supplement for joint health, may exacerbate cognitive decline in individuals already diagnosed with dementia, according to a study published in Nature Metabolism. Researchers at the University of Florida found that the supplement increased brain protein glycosylation in mouse models, leading to worsened memory deficits. In a retrospective analysis of human health records, glucosamine use was linked to a 25% higher mortality risk in patients with Alzheimer’s Disease and Related Dementias (ADRD).
How does glycosylation affect the brain?
Glycosylation is a biochemical process where complex carbohydrate molecules, or glycans, attach to proteins to ensure their stability. According to the study, this process is essential for normal neuronal communication and synaptic function. However, University of Florida researchers identified “hyperglycosylation”—an excessive attachment of glycans—as a potential metabolic driver of Alzheimer’s disease.

By using spatial multiomics and isotope-tracing in human brain tissue, the team observed that N-glycan abundance increases across both white and grey matter in Alzheimer’s-affected brains. This metabolic shift appears to interfere with neuronal membrane proteins, which are critical for synaptic transmission. While the researchers successfully improved cognitive function in mice by knocking down specific glycosylation enzymes, they found that oral glucosamine administration had the opposite effect, accelerating behavioral impairments.
The researchers estimate that over one million people in the United States living with dementia may currently be taking glucosamine. Because the supplement is available over-the-counter, its use is often under-recorded in formal medical health records.
What did the human health record analysis reveal?
The research team utilized natural language processing to screen health records for patients with ADRD or mild cognitive impairment. Approximately 8% of the patients in the study were documented glucosamine users. After adjusting for age, sex, and other demographic variables, the data indicated a 25% increase in 10-year mortality risk for those with established dementia.
The study also noted a 25% higher rate of progression from mild cognitive impairment to ADRD among glucosamine users. However, the authors emphasize that these human findings are observational and retrospective. Because health records do not always capture all over-the-counter supplement use, the researchers caution that these results demonstrate an association rather than definitive clinical proof of causation.
Why do researchers recommend clinical trials?
The link between glucosamine and worsened outcomes in dementia patients necessitates more rigorous evaluation. Current evidence suggests that while glucosamine might benefit joint health, its metabolic impact on the brain could be detrimental to those with neurodegenerative conditions. According to the study authors, there is an urgent need for double-blind clinical trials to systematically evaluate the safety of this supplement for the dementia population.
Always consult with a neurologist or primary care physician before adding new supplements to a daily regimen, especially if you have been diagnosed with cognitive impairment or dementia.
Frequently Asked Questions
Is glucosamine dangerous for everyone?
No. The study specifically highlights concerns for patients with established Alzheimer’s Disease and Related Dementias (ADRD). There is no evidence in this study suggesting similar risks for the general, cognitively healthy population.
Does glucosamine cause Alzheimer’s disease?
The study does not claim that glucosamine causes the disease. Instead, it suggests that for those who already have the condition, the supplement may contribute to a metabolic environment that accelerates cognitive decline.
Should I stop taking my joint supplements?
If you have a diagnosis of dementia or mild cognitive impairment, speak with your doctor about these findings. Do not discontinue prescribed medications or supplements without professional medical guidance.
Are you or a loved one navigating a dementia diagnosis? Subscribe to our newsletter for the latest updates on metabolic health and neurodegenerative research.












